Clearmind Medicine’s (CMND) proprietary compound could treat alcohol addiction, but that’s not all. It is now being evaluated to treat other addictive behaviours such as compulsive consumption of food, television, technology, shopping, gambling, and even sex.
Toronto, Ontario, November 8, 2021 – Clearmind Medicine Inc. (CSE: CMND, FSE:CWY0), (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under treated health problems, announced today its participation at the Wonderland MiamiConference organized by Microdose.
Wonderland Miami Conference is the largest in-person conference in the psychedelic medicine industry. The conference will take place on November 8th and 9th at the Adrienne Arsht Center for Performing Arts in Miami. The conference will offer a unique in-person convergence of business, science, music, and emerging technologies.
Wonderland Miami by Microdose is also a thought-leadership platform and an opportunity to connect with influential leaders in science, policy, and business.
The speakers list includes Drs. Matthew Johnson, Robin Carhart-Harris, and Rick Doblin. Other featured speakers at the event include Mike Tyson, former professional boxer and undisputed heavyweight champion, who has advocated for the use of psychedelic drugs, as well as Lamar Odom, a two-time NBA Champion andOlympic Gold Medalist.
Clearmind Medicine team will introduce the company at the conference. To arrange a meeting, please contact: invest@clearmindmedicine.com
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
TheCompany’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S.,Europe, China and India, with pending divisional applications in Europe and theU.S. The second, “Alcohol Beverage Substitute,” has been approved for aEuropean patent, with pending applications in the U.S., China and India. TheCompany intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation ServicesProvider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
TORONTO, Ontario, Oct. 14, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under treated health problems, today announces that professors Wim van den Brink and Gabriele Fischer have joined the Company’s scientific advisory board.
Professor van den Brink, M.D., Ph.D., is a professor of addiction psychiatry at the Academic Medical Center of the University of Amsterdam and a recognized expert in the neurobiology and pharmacological treatment of substance use disorders and behavioral addictions. His work has garnered several prestigious awards, and his influence extends across policy and academics. He holds leadership positions on a myriad of professional committees and organizations, is a sought-after keynote speaker, has co-authored close to 800 peer-reviewed papers, and currently serves on the editorial boards of seven scientific journals in the fields of psychiatry and addiction.
Professor Gabriele Fischer, M.D., is a professor of addiction research and treatment, medical director of the Addiction Clinic at the Department of Psychiatry & Psychotherapy at the Medical University of Vienna, and has acted as principle or cooperating investigator on international epidemiological clinical and psychopharmacological studies in the field of substance use disorder and nonsubstance-related addictions. She is an influential thought leader in the treatment of addiction and is a long-standing consultant for many global organizations, including the United Nations Office on Drug and Crime (UNODOC), the World Health Organization (WHO) and the European Parliament. A prominent author and speaker, Fischer has given over 400 scientific presentations, authored over 150 peer-reviewed publications, and is involved in editorial and reviewing work for many international medical journals.
Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the appointments: “Professor van den Brink and professor Fischer have both made substantial contributions to the field of substance abuse and related behaviors, advancing the way we understand and treat addiction. There are few scientists in the world with their breadth of knowledge and experience, and we are delighted to welcome them to our scientific advisory board.”
About Professor Wim van den Brink, M.D., Ph.D.
Professor van den Brink is professor of addiction psychiatry at the Academic Medical Center of the University of Amsterdam and a recognized expert in the neurobiology and pharmacological treatment of substance use disorders and related comorbidities and behavioral addictions. He is president of the International Collaboration on ADHD and Substance Abuse, a member of the scientific advisory board Swiss Research Institute Public Health & Addiction and chair of the ZonMW program on mental health research.
His work has garnered numerous awards, including the Marie Curie Award for Neuroimaging of the Neurotoxicity of Ecstasy; Lifetime Achievement Award for Science from the Netherlands Association of Psychiatry; Honorable Member of the Spanish Society for Dual disorders; European Addiction Research Award from the European Federation of Addiction Societies (EUFAS); and, most recently, Doctor et Professor Honoris Causa at the Eötvös Loránd University in Budapest.
His influence extends across policy and academics and includes chairing the workgroups that developed the Dutch treatment guidelines for alcohol use disorders, opiate addiction and drugs other than opioids; the Scientific Program Committee of European College of Neuropsychopharmacology (ECNP); the advisory board Netherland Dialectical Behavioral Treatment; Netherlands National Quality Committee on Mental Health; and executive board Mainline Harm-Reduction.
A prolific writer, he is the co-author of more than 600 international peer-reviewed scientific papers. Until recently, he was an associate editor of Drug and Alcohol Dependence and chief editor of European Addiction Research and remains a member of the editorial boards of seven other psychiatric/addiction scientific journals.
Professor van den Brink received his medical degree from the Free University in Amsterdam and earned his Ph.D. at The State University of Groningen. During his tenure at the University of Amsterdam, he served as senior researcher, Dept. of Psychiatry; assistant professor of psychiatry; and professor of addiction psychiatry. He was also a Fellow Psychiatric Epidemiology at Columbia University in New York.
About Professor Gabriele Fischer
Professor Gabriele Fischer is a professor for psychiatry – addiction research and treatment; medical director of the Addiction Clinic, Department of Psychiatry & Psychotherapy at the Medical University of Vienna, a research facility and treatment center for patients with substance use disorders and nonsubstance dependence (e.g., pathological gamblers); and leader of the University’s Center for Public Health “Addiction in Public Health” project.
Professor Fischer has acted as principle or cooperating investigator on projects in the EU, the U.S. and Afghanistan regarding investigations on alternatives to coercive sanctions in patients with substance use disorders. Her work is typically focused on eliciting the views of key stakeholders from both health/welfare and justice sectors and advocates for early intervention, with an eye to not only increase the patient’s quality of life but also reduce societal costs.
Professor Fischer is a prominent author and speaker with more than 140 peer-reviewed publications and 400 presentations and is a member of multiple international scientific associations. Most noteworthy, she is a long-standing consultant for several international and national groups, including the United Nations Office on Drug and Crime (UNODOC), the World Health Organization (WHO) and the European Parliament. She is a member of the Scientific Board for Quality Control and Quality Management in Medicine and of the European Monitoring Center for Drugs and Drug addiction (EMCDDA), member of the General Medical Council in Austria, founding board member of Women for Women: Health Policy in Focus, and commission director of the Austrian Ombudsman Board dedicated to improving human rights in vulnerable populations.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com
The Regulatory affairs and CRO will oversee the Company’s efforts to secure an IND review of MEAI as a potential treatment forAlcohol Use Disorder and binge drinking
Toronto, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0),(“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under treated health problems, today announced that it has engaged Clinipace Incorporated, a full service Contract Research Organization (CRO), to advise the Company in its pursuit of Food and Drug Administration(FDA) approval for its therapeutics.
Clinipace’s first project will be coordinating the submission of a request for an Investigational New Drug (IND) review by the FDA of theCompany’s proprietary MEAI compound for the treatment of alcohol use disorder (AUD) and binge drinking in preparation for Phase I clinical study in humans.
MEAI (5-Methoxy-2-aminoindane) is a novel psychoactive molecule, exerting a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages. The Company owns six patents covering the use of MEAI for the treatment of AUD and binge behaviour. Pre-clinical study results for MEAI demonstrated a high safety profile and promising efficacy, further supporting the Company’s decision to pursue an IND Review.
Adi Zuloff-Shani, PhD., CEO of Clearmind, commented, “Moving any drug through the FDA approval process requires deep expertise and meticulous attention to detail; this is particularly true for psychedelics. We chose Clinipace as our CRO as they have facilitated dozens of successful regulatory submissions operating at the highest clinical and ethical standards.”
“With this partnership, we are well positioned to advance through the review process in a timely and efficient manner, bringing us closer to establishing MEAI as the basis for changing the way we treat alcohol abuse and other addictive behaviour,” Zuloff-Shani concluded.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behaviour Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,”has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt StockExchange under the symbol “CWY0.”
For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.comTelephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in theUnited States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of theCSE) accepts responsibility for the adequacy or accuracy of this release.
Wire Service Contact
InvestorWire
Los Angeles, California
www.InvestorWire.com
212.418.1217
Editor@InvestorWire.com
Anexpert panel will present and discuss new potential treatments for Alcohol UseDisorder and binge drinking
TORONTO,Oct. 1, 2021—via InvestorWire – Clearmind Medicine Inc. (CSE:CMND) (“Clearmind” or the “Company“), a psychedelicmedicine biotech company focused on the discovery and development of novelpsychedelic-derived therapeutics to solve widespread and undertreated healthproblems, is pleased to announce it will be hosting Psychedelics ForAlcoholism, a free, live virtual event highlighting new potentialtreatments for alcohol use disorder and binge drinking.
The online event will be held Oct. 20, 2021, starting at 12 p.m.EST/9 a.m. PST; registration is open and free to all. The event will includebrief presentations by featured speakers, followed by a discussion with aquestion-and-answer session.
The Company has curated a panel of scientists, thought leaders,therapists, and pundits to sharetheir experiences and educate participants on the mounting evidence suggestingthe effectiveness of psychedelics, and specifically MEAI, in the regulation ofexcessive drinking .
Representatives from the Company will also provide an updateon Clearmind’s MEAI-based medicines and their potential for the treatment ofAlcohol Use Disorder and binge drinking.
AdiZuloff-Shani, Ph.D., CEO of Clearmind, stated, “We’re in the middle of a PsychedelicRenaissance that is revolutionizing the way we treat mental disorders. We putthis event together to increase awareness of the advances being made in thefield, and more specifically generate awareness of the work Clearmind is doingwith regard to alcohol use and binge drinking.”
“Togetherwith our sponsors and partners, we are eager to share our progress and provideaccess to accurate information to interested communities, including mentalhealth practitioners, researchers, potential patients, investors and thegeneral public,” Zuloff-Shaniconcluded.
Following is a list ofour panelists and partners. To register for the event, or learn more aboutPsychedelics for Alcoholism, visit the event website.
Among our featured speakers and panelists: Shannon Smadella, moderator; Adi Zuloff-Shani, Ph.D., chief executive officer at Clearmind; Mark Haden, Advisory Board member,Clearmind; Terri Freeland, construction industry professional; and Dr. JeffMorley, registered psychologist.
Partners include: Canadian Psychedelic Association, WorldPsychedelics Day, McKennaAcademy of Natural Philosophy™, and Insight Global.
About Clearmind Medicine Inc.
Clearmind (CSE: CMND) is a psychedelicpharmaceutical biotech company focused on the discovery and development ofnovel psychedelic-derived therapeutics to solve widespread and underservedhealth problems, including alcohol use disorder. Its primary objective is toresearch and develop psychedelic-based compounds and attempt to commercializethem as regulated medicines, foods or supplements.
The Company’s intellectual portfoliocurrently consists of two patent families. The first, “Binge BehaviorRegulators,” has been granted in the U.S., Europe, China and India, withpending divisional applications in Europe and the U.S. The second, “AlcoholBeverage Substitute,” has been approved for a European patent, with pendingapplications in the U.S., China and India. The Company intends to seekadditional patents for its compounds whenever warranted and will remainopportunistic regarding the acquisition of additional intellectual property tobuild its portfolio.
Shares of Clearmind are listed fortrading on the Canadian Securities Exchange under the symbol “CMND“and the Frankfurt Stock Exchange under the symbol “CWYO”.
For further information, pleasecontact:
Investor Relations Email:
Telephone: (778) 400-5347
General Inquiries Email:
FORWARD-LOOKINGSTATEMENTS:
Thisnews release may contain forward-looking statements and information based oncurrent expectations. These statements should not be read as guarantees offuture performance or results. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements.Such statements include submission of the relevant documentation within therequired timeframe to the satisfaction of the relevant regulators and raisingsufficient financing to complete the Company’s business strategy. There is nocertainty that any of these events will occur. Although such statements arebased on management’s reasonable assumptions, there can be no assurance thatsuch assumptions will prove to be correct. We assume no responsibility toupdate or revise them to reflect new events or circumstances.
Investinginto early-stage companies inherently carries a high degree of risk, andinvestment into securities of the Company shall be considered highlyspeculative.
Thispress release shall not constitute an offer to sell or the solicitation of anoffer to buy, nor shall there be any sale of, the securities in any province inwhich such offer, solicitation or sale would be unlawful. The securitiesissued, or to be issued, under the Private Placement have not been, and willnot be, registered under the United States Securities Act of 1933, as amended,and may not be offered or sold in the United States absent registration or anapplicable exemption from registration requirements.
Neitherthe Canadian Securities Exchange (the “CSE”) nor its Regulation ServicesProvider (as that term is defined in the policies of the CSE) acceptsresponsibility for the adequacy or accuracy of this release.
WireService Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com
Toronto, Ontario–(Newsfile Corp. – September 27, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has entered an agreement to fund a second research and development project with Yissum Research Development Company (“Yissum”), the technology transfer company of The Hebrew University of Jerusalem.
The project is consistent with the Company’s focus on developing novel therapies that improve mental health, particularly those relating to addiction, binge behavior and depression.
About Yissum Research Development Corporation
Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,875+ patents globally; licensed over 1140+ technologies and has spun out more than 191 companies. Yissum’s business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further information please visit www.yissum.co.il.
About the Hebrew University of Jerusalem
The Hebrew University of Jerusalem is Israel’s first university, formed in 1918 and opened in 1925. Today, there are over 23,000 students enrolled at the University, including undergraduates, master’s degree students, and doctoral candidates. The university has four campuses: Mount Scopus, The Edmond J. Safra (Givat Ram) Campus, and Ein Kerem (in Jerusalem), and Rehovot. Hebrew University Alumni are invited to visit https://new.huji.ac.il.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators”, has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWYO.”
For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE“) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Not for distribution to U.S. newswire services or dissemination in the United States.
TORONTO,September 1, 2021, Clearmind Medicine Inc. (CSE: CMND) (“Clearmind”or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that all resolutions were duly passed by shareholders at the Company’s Annual and Special Meeting held on September 1, 2021.
“I am pleased to welcome Oz and Oded to our Board of Directors. Together, they bring decades of experience in corporate finance and accounting – areas that are critical to an emerging public company. Both gentlemen have diverse backgrounds in business, management, and leadership, and I know their insight will be invaluable as we work together to establish Clearmind as a leading creator of novel therapeutics for treating mental health issues,”commented Adi Zuloff-Shani, Ph.D., CEO of Clearmind.
OdedGilboa
Mr.Gilboa brings over 20 years of experience in finance and public accounting,having served as a senior finance executive in the technology and biotech industries with responsibilities in corporate finance, accounting, strategic planning and operational and financial management.
Gilboa’s prior positions include CFO of several public companies; CannaPowder Inc.(OTCQB: CAPD) a biomedical company focused on the nutraceutical industries, Emerald Medical Applications Corp. (OTCQB: MRLA) developer of a medical application for the early detection of skin cancer and BreedIt Corp (OTCQB: BRDT) an aggrotech company focused on the development of advanced agriculture breeding. Other financial positions include, Revenue Manager of Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), Director of Finance and US Controller of Taro Pharmaceuticals (NASDAQ:TAROF), and Director of Finance at IDT Corporation(NYSE:IDT), a worldwide provider of telecommunications and media services.
Mr.Gilboa is a CPA with licenses in the US and Israel. He graduated with a B.A in Economics and Accounting degree from Tel-Aviv University and an M.B.A. from Recanati Business School also at Tel-Aviv University.
OzAdler
Mr.Adler currently serves as Chief Financial Officer of SciSparc Ltd (OTC:SPRCF) and sits on the Board of Elbit Imaging Ltd and Charging Robotics Ltd., and previously served as the Chief Financial Officer of Medigus Ltd.
Mr.Adler worked in the audit department of Kost Forer Gabbay & Kasierer, amember of Ernst & Young Global. Mr. Adler is a certified public accountant in Israel and holds a B.A. degree in Accounting and Business Management from The College of Management, Israel.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of two patent families. Thefirst, “Binge Behavior Regulators”, has been granted in the U.S.,Europe, China and India, with pending divisional applications in Europe and theU.S. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND.”
For further information, please contact:
Investor Relations,
Email:invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended,and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Shares To Be Dually Listed On Canadian Securities Exchange
TORONTO,Aug. 17, 2021– Clearmind Medicine Inc. (CSE: CMND) (“Clearmind”or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce the listing of its common shares for trading on the Frankfurt Stock Exchange (“FSE”) under the symbol CWY0.
The FSE is the world’s third largest trading exchange, ranking only behind the New York Stock Exchange and NASDAQ. Home to public companies from more than 80 different countries, the FSE represents over 1.4 million securities and generates more than €1 trillion trading volume annually.
“We are very pleased to have Clearmind shares dually -listed on the Frankfurt Stock Exchange. The increased visibility will help strengthen trading liquidity and facilitate investment in the Company by institutional and retail investors across Europe. The psychedelic drug market is expected to surpass $10 billion by 2027, and we believe Clearmind shares provide an excellent opportunity to participate in that growth,“ commented Adi Zuloff-Shani, Ph.D., CEO of Clearmind.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators”, has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation ServicesProvider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Initial Focus on MEAI ClinicalTrial Protocol
TORONTO,Aug. 3, 2021 — Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the”Company“), a psychedelic medicine biotech company focused onthe discovery and development of novel psychedelic-derived therapeutics tosolve widespread and undertreated health problems, announces that Mark Hadenhas joined the Company’s Scientific Advisory Board (the “SAB”). The SAB’sinitial focus will be providing guidance on the Company’s request for anInvestigational New Drug review from the US Food and Drug Administration (“FDA”)for MEAI, for treating Alcohol Use Disorder (“AUD”).
Arecognized leader in the field, Mr. Haden has spent his career working toadvance the use of psychedelics in medicine. He currently serves as director ofclinical research at Psygen Industries, a manufacturer of pharmaceutical-gradepsychedelic drug products for clinical research and therapeutic applicationsand is an adjunct professor at the University of British Columbia School ofPopulation and Public Health.
Mr.Haden has substantial research experience, including a leadership role in thePRIME study (Psilocybin Research Investigating Medical Efficacy), whichexplores psilocybin as an adjunct in the treatment of substance use disorders,and he has spent 10 years as the chairman and executive director of MAPS Canada(Multidisciplinary Association for Psychedelic Studies), an organization hefounded. He has also dedicated over 25 years to working directly with patientsthrough the Vancouver Coastal Health Addiction Services at the Pacific SpiritCommunity Health Centre.
Heis a frequent keynote speaker on the topic of psychedelics and has beenpublished in a number of journals, including the Canadian Journal of PublicHealth, International Journal of Drug Policy, Encyclopedia of Public Health,Harm Reduction Journal, Open Medicine, Journal of Psychoactive Drugs, and theJournal of Studies on Alcohol and Drugs. He was also instrumental in helpingthe Health Officers Council of British Columbia develop their position papers,lectures and presentations on issues regarding the regulation of illegal drugs.
“Markis an important addition to our SAB. He is one of the world’s leading advocatesfor the legalization of psychedelics and a strong proponent of their medicinalvalue. His research into psychedelics and their potential to treat addictionparallels the work we are doing to develop therapies to manage AUD, and I amconfident that his contribution to our efforts to secure FDA approval for MEAI willbe invaluable,” commented Adi Zuloff-Shani, Ph.D., CEO of Clearmind.
Mr.Haden noted, “Clearmind’s innovative approach to harnessing the propertiesof psychedelics to create therapeutics for mental health issues has thepotential to change millions of lives around the world. I have spent my careeron a similar quest, and I am delighted to facilitate this effort in any way Ican. I very much look forward to working with the talented team at Clearmind aswell as the other distinguished members of the advisory board.”
AboutClearmind Medicine Inc.
Clearmindis a psychedelic pharmaceutical biotech company focused on the discovery anddevelopment of novel psychedelic-derived therapeutics to solve widespread and underservedhealth problems, including alcohol use disorder. Its primary objective is to researchand develop psychedelic-based compounds and attempt to commercialize them asregulated medicines, foods or supplements.
TheCompany’s intellectual portfolio currently consists of two patent families. Thefirst, “Binge Behavior Regulators”, has been granted in the U.S.,Europe, China and India, with pending divisional applications in Europe and theU.S. The second, “Alcohol Beverage Substitute”, has been approved for aEuropean patent, with pending applications in the U.S., China and India. TheCompany intends to seek additional patents for its compounds whenever warrantedand will remain opportunistic regarding the acquisition of additional intellectualproperty to build its portfolio.
Sharesof Clearmind are listed for trading on the Canadian Securities Exchange underthe symbol “CMND.”
For further information, please contact:
Investor Relations,
Email:invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
FORWARD-LOOKING STATEMENTS:
Thisnews release may contain forward-looking statements and information based oncurrent expectations. These statements should not be read as guarantees offuture performance or results. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements.Such statements include submission of the relevant documentation within therequired timeframe to the satisfaction of the relevant regulators and raisingsufficient financing to complete the Company’s business strategy. There is nocertainty that any of these events will occur. Although such statements arebased on management’s reasonable assumptions, there can be no assurance thatsuch assumptions will prove to be correct. We assume no responsibility toupdate or revise them to reflect new events or circumstances.
Investinginto early-stage companies inherently carries a high degree of risk, andinvestment into securities of the Company shall be considered highlyspeculative.
Thispress release shall not constitute an offer to sell or the solicitation of anoffer to buy, nor shall there be any sale of the securities in any province inwhich such offer, solicitation or sale would be unlawful.
Neitherthe Canadian Securities Exchange (the “CSE”) nor its Regulation ServicesProvider (as that term is defined in the policies of the CSE) acceptsresponsibility for the adequacy or accuracy of this release.
Dear Shareholders,
As Clearmind’s new CEO, I would like to take this opportunity to welcome you as ashareholder, introduce myself and give you an update on the Company aswell as some insight regarding our plans going forward.
I trust by now you are aware that this past May we finalized a Change ofBusiness Listing on the Canadian Stock Exchange (CSE). In conjunction with thelisting, the Company changed its name from Cyntar Ventures Inc. to ClearmindMedicine Inc. to better reflect our shift to the research and development ofinnovative psychedelic therapeutics. As of May 26th, shares of Clearmind havebeen trading on the CSE under the symbol “CMND.”
As we announced last week, I was recently appointed as the Company’sCEO. I first joined Clearmind as a member of the Scientific Advisory Board. AsI became more involved in the Company and reviewed the pre-clinical testingresults, I recognized real commercial potential. So, when I was offered theposition of CEO, I jumped at the opportunity to initiate the regulatoryapproval process for our 5-Methoxy-2-aminoindane (MEAI), a novel syntheticsmall molecule psychedelic, with Alcohol Use Disorder (AUD) as the initialindication. Further to that, it is my intention to use my experience to build aviable proprietary psychedelic-centric product pipeline for Clearmind.
Why Psychedelics?
A researcher at heart, I was intrigued by the mounting evidencesupporting the “Psychedelic Renaissance,” particularly for the treatment ofmental health disorders, where existing therapies can be ineffective and areoften associated with adverse side effects.
The FDA seems receptive to the possibilities; they have easedrestrictions on research into psychedelic-based pharmaceuticals and theyrecently granted the first Breakthrough Therapy designation to twopsilocybin-based drugs for the treatment of Major Depressive Disorder.
Another promising indicator: several states have proposed or arecurrently preparing legislation permitting psilocybin use for medical purposes.
Our Mission
Clearmind’s mission is to leverage the properties of our compounds todevelop novel therapeutics that address prevalent mental health conditionswhich are under-treated or lacking effective treatments today, such asaddictions.
Our leading compound, MEAI, is designed to address AUD, binge drinkingand other binge behavior prevention, as well as addiction, conditions thataffect over 13 million people in the U.S. alone.
MEAI is a novel psychoactive aminoindane derivative that simulates theeuphoric alcohol-like experience while reducing the desire to consume alcohol.
Pre-clinicalstudy results were extremely favorable, demonstrating a high safety profile andpromising efficacy. We are now beginning the process of requesting anInvestigational New Drug (IND) review with the FDA. The first step is a pre-INDmeeting, after which an IND submission will be filed in preparation for phase Iclinical study in humans.
IP Portfolio
Intellectual Property is the primary asset of any pharmaceuticalcompany, and as such it is critical that we protect the proprietary nature ofour intellectual property, whether it is our compounds, formulations,indications, etc., as well as the investment of time and capital we have allmade in the Company. This is especially important now, as researchers and pharmaceuticalcompanies begin to recognize that the benefits and potential applications for psychedelictreatments represent a substantial market opportunity.
The Clearmind IP Portfolio currently comprises two patent families; bingebehavior regulators which have been granted approval in the U.S., Europe,China, and India, as well as pending divisional applications in Europe and theUS. Our alcohol beverage substitute has been approved for a European patent,with pending applications in the US, China, and India.
We are seeking additional patents to expand not only our IP portfoliobut also our therapeutic solutions for underserved conditions.
Financial Summary
I am happy to report that Clearmind is financially sounder since theChange of Business listing. In addition to eliminating obligations related tothe previous business, we recently secured $6.2 million in private placement.The capital raised strengthens our balance sheet and provides us funding forour current R&D plan, and since the offering was a unit deal, the warrants,if exercised, present the possibility for additional future capital.
Looking Ahead
I believe psychedelic-based medicine has the potential to revolutionizethe way we treat mental health issues. Clearmind is committed to creatingeffective therapies that will better the lives of millions. Our management teamhas the expertise and passion necessary to achieve that objective, and we haveattracted a world-class Scientific Advisory Board to help us become a leader inthe field.
I would like to thank you for your continued support along this journeyand look forward to sharing more good news with you soon.
Sincerely,
Adi Zuloff-Shani, PhD.
Chief Executive Office
If you would like more information on our recent progress, we invite youto read the listing documents posted on the Exchange website www.thecse.com.
Learn more at:
www.Clearmindmedicine.com
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
FORWARD-LOOKINGSTATEMENTS:
This news release may containforward-looking statements and information based on current expectations. Thesestatements should not be read as guarantees of future performance or results.Such statements involve known and unknown risks, uncertainties and other factorsthat may cause actual results, performance or achievements to be materiallydifferent from those implied by such statements. Such statements includesubmission of the relevant documentation within the required timeframe to thesatisfaction of the relevant regulators and raising sufficient financing tocomplete the Company’s business strategy. There is no certainty that any ofthese events will occur. Although such statements are based on management’sreasonable assumptions, there can be no assurance that such assumptions willprove to be correct. We assume no responsibility to update or revise them toreflect new events or circumstances.
Investing into early-stagecompanies inherently carries a high degree of risk and investment intosecurities of the Company shall be considered highly speculative.
This press release shall notconstitute an offer to sell or the solicitation of an offer to buy nor shallthere be any sale of the securities in any province in which such offer,solicitation or sale would be unlawful. The securities issued, or to be issued,under the Private Placement have not been, and will not be, registered underthe United States Securities Act of 1933, as amended, and may not be offered orsold in the United States absent registration or an applicable exemption fromregistration requirements.
Neither the CanadianSecurities Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the CSE) accepts responsibility for the adequacy oraccuracy of this release.
Not for distribution to U.S. newswire services or dissemination in theUnited States.
